Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Cognition Therapeutics Inc (NASDAQ: CGTX) was $0.32 for the day, up 1.02% from the previous closing price of $0.31. In other words, the price has increased by $1.02 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
Our analysis of CGTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.09. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 19, 2024, Upgraded its rating to Buy and sets its target price to $1.50 from $1 previously.
On November 03, 2021, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on November 03, 2021, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 31 ’25 when Ricciardi Lisa bought 38,851 shares for $0.77 per share. The transaction valued at 30,001 led to the insider holds 38,851 shares of the business.
Stock Price History:
Over the past 52 weeks, CGTX has reached a high of $2.54, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is -8.82%, while the 200-Day Moving Average is calculated to be -36.36%.
Shares Statistics:
A total of 61.97M shares are outstanding, with a floating share count of 50.25M. Insiders hold about 18.94% of the company’s shares, while institutions hold 9.13% stake in the company.
